Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...
Some physicians who were not involved in the research cautioned that the study period was too short to draw firm conclusions, The Wall Street Journal reported. Researchers acknowledged longer-term ...